A Study to Compare Effects and Safety of CT-P51 and Keytruda in Patients With Previously Untreated Metastatic Lung Cancer

ConditionNon Squamous Non Small Cell Lung Cancer

Trial statusRecruiting

Trial phasePhase 3

Trial typeInterventional

Biological sexAll

Age18+

SponsorCelltrion

About this trial

The goal of this Phase 3 clinical trial is to compare efficacy and safety of CT-P51 and European Union (EU) approved Keytruda in combination with platinum pemetrexed chemotherapy in patients with previously untreated metastatic nsNSCLC.

Eligibility criteria

Qualifiers

Stage IV, non squamous NSCLC

Have not received any prior systemic anti-cancer therapy for metastatic NSCLC

Have at least 1 measurable lesion per RECIST version 1.1

Disqualifiers

Have predominantly squamous cell histology NSCLC.

Hypersensitivity or contraindication to any component of the study drug, pemetrexed and cisplatin or carboplatin

Trial design

Treatments tested in this trial

CT-P51
EU-approved Keytruda

Treatment groups

606 Participants

are divided into 2 treatment groups

Sponsors and collaborators

Celltrion

Lead sponsor

Source ClinicalTrials.gov